Access Medical Ventures
VC Fund
Tel Aviv, Israel
Access Medical Ventures is a U.S based venture capital fund that focuses specifically on investing and advancing medical device start-ups. AMV’s primary interest is investing in interventional and therapeutic medical device start-ups, along with the variety of all the medical disciplines.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Access Medical Ventures invests in
Stages Access Medical Ventures invests in
Countries Access Medical Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 1 (20%)
- Manufacturing 1 (20%)
- Medical Device 1 (20%)
Stage
- Series A 2 (40%)
- Series D 1 (20%)
- Funding Round 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Tal
Partner
|
Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Automate AI
|
Automate AI Medical is reimagining the future of healthcare with intelligent, personalized, and proactive wellness solutions—powered by cutting-edge artificial intelligence.Our platform combines real-time health monitoring, predictive analytics, and conversational AI to deliver a seamless healthcare experience tailored to each individual. Whetheryou’re a patient managing chronic conditions, a provider seeking smarter diagnostics, or a researcher optimizing clinical insights, Automate AI Medical empowers you with actionable, data-driven intelligence.We serve: • Patients – with AI wellness companions and 24/7 health monitoring • Healthcare Providers – with advanced diagnostic tools and intelligent alerts • Researchers – with scalable analytics and anomaly detection • Pharma & Life Sciences – with AI models that accelerate drug discovery and trialsCore Features ✓ Real-time vitals dashboard ✓ Predictive health modeling ✓ Intelligent chat assistants ✓ Seamless EHR/data integrations ✓ HIPAA-compliant infrastructureAutomate AI Medical makes healthcare more human—by letting AI handle the complexity, so you can focus on care, prevention, and peace of mind.Join us as we reshape modern wellness. Contact us to explore careers, our platform, discuss partnerships, pilots, and early access opportunities. | $2M / Series A / Jun 20, 2025 | |
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Oct 29, 2013 | |
|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Jul 09, 2012 | |
|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Series D / Feb 01, 2012 | |
|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | $695K / Series A / Apr 11, 2009 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Access Medical Ventures invest in?
Access Medical Ventures invests primarily in Health Care, Manufacturing and Medical Device startups, most often at Series A and Series D stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Access Medical Ventures?
Public channels for Access Medical Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Access Medical Ventures?
The team at Access Medical Ventures includes Michael Tal (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
